{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0044178\nAge: 73\nGender: Female\nSample ID: P-0044178-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Pancreatic Neuroendocrine Tumor\nSample Type: Metastasis\nTumor Purity: 80.0%\n=============\nDNA Variants:\nBMPR1A c.200G>A (p.C67Y) - in 10.00% of 163 reads\nDAXX c.1617_1632del (p.P540Lfs*11) - in 14.00% of 162 reads\nMEN1 c.757_775delinsA (p.D253_L259delinsM) - in 6.00% of 337 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nFGFR3 - FGFR3 (INVERSION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic Neuroendocrine Tumor\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Everolimus\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": \"FGFR3 structural variant (inversion)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021944s017lbl.pdf\"\n  }\n}"
}